Optimal strategy for treatment of atherosclerotic cardiovascular disease—comparison of clopidogrel-based antiplatelet agent treatment versus aspirin plus low dose rivaroxaban therapy (OACART study): a study protocol for a multicenter, open-label, ran

Recent studies have demonstrated the superior benefits of clopidogrel compared to aspirin in reducing mortality, myocardial infarction, stroke, and hospitalization in chronic stable patients with coronary stenting. Furthermore, dual pathway inhibition by combining low-dose rivaroxaban with aspirin (DPI) has shown superior effects in preventing cardiovascular death, myocardial infarction, and stroke in stable atherosclerotic patients. However, no studies have directly compared these treatment strategies in the same population. This randomized controlled trial aims to compare clopidogrel-based antiplatelet therapy with or without aspirin (CAPT) to DPI in a 1:1 ratio in patients with high-risk coronary artery disease (CAD) or in patients with both CAD and peripheral artery disease (PAD). Optimal strategy for treatment of A therosclerotic cardiovascular disease—comparison of C lopidogrel-based A ntiplatelet agent treatment versus aspirin plus low dose R ivaroxaban T herapy (OACART) trial is a randomized multi-center study comparing the performance of the maintaining CAPT or DPI in a 1:1 ratio. The trial is powered for the non-inferiority of the CAPT in patients with chronic stable high-risk CAD or CAD+PAD to DPI with respect to the primary and secondary efficacy endpoints at 36 months. Between November 2023 and April 2026, we will recruit 2758 participants from multi-center in Korea, and we will examine the net clinical outcome, including all-cause death, any myocardial infarction, any stroke, any ischemia-driven revascularization (CAD or PAD), acute limb ischemia, any major or minor amputations, any acute thromboembolism, and International Society on Thrombosis and Haemostasis major bleeding at 36 months after study enrollment. OACART trial will provide the optimal antithrombotic treatment strategy for patients with stable high-risk atherosclerosis. Clinical Research Information Service (CRIS) of Republic of Korea, KCT0008458, registered on May 22, 2023. https://cris.nih.go.kr/cris/search/detailSearch.do?seq=28968&search_page=L

Authors

Institutions

Publication Details

Journal
Trials
Published
2026-07-30
DOI
https://doi.org/10.1186/s13063-026-09899-7
Primary Topic
Antiplatelet Therapy and Cardiovascular Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Optimal strategy for treatment of atherosclerotic cardiovascular disease—comparison of clopidogrel-based antiplatelet agent treatment versus aspirin plus low dose rivaroxaban therapy (OACART study): a study protocol for a multicenter, open-label, ran

Jin Joo Park, Young Jin Choi, Hyoung-Won Cho, Cheol Woong Yu et al.
Trials
Antiplatelet Therapy and Cardiovascular Diseases
article

Optimal strategy for treatment of atherosclerotic cardiovascular disease—comparison of clopidogrel-based antiplatelet agent treatment versus aspirin plus low dose rivaroxaban therapy (OACART study): a study protocol for a multicenter, open-label, ran

Jin Joo Park, Young Jin Choi, Hyoung-Won Cho, Cheol Woong Yu, Jung‐Won Suh, Ju-Seung Kwun, Tae‐Jin Youn, Pil‐Ki Min, Young Jin Youn, Chang‐Hwan Yoon, Janghyun Cho, Si‐Hyuck Kang, Tae Soo Kang, Ki‐Hyun Jeon, Seung‐Woon Rha, Jin‐Ok Jeong, Hyun‐Jae Kang, Young‐Guk Ko, Wonjae Lee, Sang‐Don Park, Seung-Uk Lee, Bong-Ki Lee, In-Ho Chae, Kyoung-Ha Park, Yun-Hyeong Cho, Sanghoon Shin, Sang-Rok Lee, Ji-Yong Jang, Deok-Kyu Cho, Jae-Kwang Lee, Song-Yi Kim, Jae-Hwan Lee, Ju Han Kim
article en

Abstract

Recent studies have demonstrated the superior benefits of clopidogrel compared to aspirin in reducing mortality, myocardial infarction, stroke, and hospitalization in chronic stable patients with coronary stenting. Furthermore, dual pathway inhibition by combining low-dose rivaroxaban with aspirin (DPI) has shown superior effects in preventing cardiovascular death, myocardial infarction, and stroke in stable atherosclerotic patients. However, no studies have directly compared these treatment strategies in the same population. This randomized controlled trial aims to compare clopidogrel-based antiplatelet therapy with or without aspirin (CAPT) to DPI in a 1:1 ratio in patients with high-risk coronary artery disease (CAD) or in patients with both CAD and peripheral artery disease (PAD). Optimal strategy for treatment of A therosclerotic cardiovascular disease—comparison of C lopidogrel-based A ntiplatelet agent treatment versus aspirin plus low dose R ivaroxaban T herapy (OACART) trial is a randomized multi-center study comparing the performance of the maintaining CAPT or DPI in a 1:1 ratio. The trial is powered for the non-inferiority of the CAPT in patients with chronic stable high-risk CAD or CAD+PAD to DPI with respect to the primary and secondary efficacy endpoints at 36 months. Between November 2023 and April 2026, we will recruit 2758 participants from multi-center in Korea, and we will examine the net clinical outcome, including all-cause death, any myocardial infarction, any stroke, any ischemia-driven revascularization (CAD or PAD), acute limb ischemia, any major or minor amputations, any acute thromboembolism, and International Society on Thrombosis and Haemostasis major bleeding at 36 months after study enrollment. OACART trial will provide the optimal antithrombotic treatment strategy for patients with stable high-risk atherosclerosis. Clinical Research Information Service (CRIS) of Republic of Korea, KCT0008458, registered on May 22, 2023. https://cris.nih.go.kr/cris/search/detailSearch.do?seq=28968&search_page=L

Trials
Ewha Womans University (KR), Seoul National University (KR), Yonsei University (KR), Chungnam National University (KR), Korea University (KR), Severance Hospital (KR), Korea University Medical Center (KR), Seoul National University Hospital (KR), Seoul National University Bundang Hospital (KR), Suncheon Jeil College (KR), Kwangju Christian Hospital (KR), Chonnam National University Hospital (KR), Wonju Severance Christian Hospital (KR), Korea Institute of Materials Science (KR), Kangwon National University Hospital (KR), Sejong General Hospital (KR), Jeonbuk National University Hospital (KR), National Health Insurance Service Ilsan Hospital (KR), Chungnam National University Hospital (KR), Myongji Hospital (KR), Gangnam Severance Hospital (KR), Inha University Hospital (KR), National Health Insurance Service (KR), Hallym University Sacred Heart Hospital (KR), Yonsei University Health System (KR), Jeju National University Hospital (KR), Chungnam National University Sejong Hospital (KR), Ewha Womans University Seoul Hospital (KR), Bucheon University (KR), Jeonbuk National University (KR), Jeju National University (KR), Dankook University (KR)
Yuhan
Good health and well-being
Openalex Percentile: Top 9%
Antiplatelet Therapy and Cardiovascular Diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.